Dipen J. Parekh, M.D., robotic surgeon and urologic oncologist at Sylvester Cancer Center, and Professor and Chairman of department of Urology, commented: "We are extremely delighted at doing the first cases using the revolutionary robotic EDAP HIFU system on men with prostate cancer. All of our patients left the hospital within four hours of their procedure. This is a truly noninvasive technique exploring focal ablation in men with prostate cancer with the potential of significantly reducing treatment related morbidity, especially urinary incontinence and sexual dysfunction. We look forward to benefiting appropriate patients with prostate cancer using this state of the art technology."
Marc Oczachowski, EDAP TMS Chief Executive Officer, added: "We are very pleased with the first Ablatherm Robotic HIFU treatments recently performed at Sylvester Center following the Ablatherm sale recorded at the end of 2015. We expect Sylvester Center Urology Department, headed by Dr. D.J. Parekh, will become the training and proctoring center for Ablatherm HIFU in the U.S."
Oczachowski, continued: "With our proven leadership in HIFU for prostate tissue ablation, we are convinced that partnering with luminary academic and reference centers in the U.S. will help establish our superior technology and its clinical recognition. We believe Ablatherm adoption by U.S. urologists will be strengthened and accelerated by the proctoring assistance of Ablatherm key experts in the use of Ablatherm HIFU who are already recognized experts in the field of Prostate Cancer Robotic Surgery. We, at EDAP, are building the future of Ablatherm HIFU in the U.S. with the support of key scientific and clinical leaders. Bringing Ablatherm Robotic HIFU to U.S. patients is our priority."